Himuka is a clinical-stage biotech company engaged in the research and development of novel therapies for unmet medical needs. Himuka is conducting a Phase 1 clinical trial of HM201, a novel adrenomedullin based peptide drug candidate developed for the treatment of Inflammatory bowel disease.
Company Details
- Founded
- -
- Address
- 2-5-36 Takachiho-Dori, Miyazaki,miyazaki 8800812,japan
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.himuka-am.com/
- HQ
- Miyazaki, Miyazaki
Himuka Am Pharma / Himuka Am Australia Questions
Himuka Am Pharma / Himuka Am Australia's website is https://www.himuka-am.com/
Himuka Am Pharma / Himuka Am Australia's LinkedIn profile is https://jp.linkedin.com/company/himuka-am
Himuka Am Pharma / Himuka Am Australia's industry is
Biotechnology Research
Himuka Am Pharma / Himuka Am Australia's top competitors are
Zuellig Pharma Ssg Australia,
Point Pharma Australia Pty. Ltd.,
Sn Pharma Australia Pty Ltd,
Dr Falk Pharma Australia,
Trident Pharma (Australia),
Teva Pharma Australia Pty Ltd.
Himuka Am Pharma / Himuka Am Australia's categories are Biotechnology Research
Himuka Am Pharma / Himuka Am Australia's founding year is 2017
